CAPRELSA (kap-rel-sah) is a prescription medicine for adults. It is the first FDA-approved medication to treat advanced medullary thyroid cancer (MTC).
CAPRELSA® - the first tyrosine kinase inhibitor approved so far by the European Medicines Agency (EMA) for the treatment of advanced medullary thyroid cancer (MTC).
CAPRELSA® is indicated for the treatment of aggressive and symptomatic MTC in patients with unresectable locally advanced or metastatic disease. For patients in whom Rearranged during Transfection (RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.
CAPRELSA® is an orally active small molecule, multitargeted tyrosine kinase inhibitor that blocks selectively Vascular Endothelial Growth Factor Receptor (VEGFR), Epidermal growth factor receptor (EGFR) and Rearranged During Transfection (RET) signalling.
The clinical efficacy of CAPRELSA® in advanced MTC has been demonstrated in a randomized, double-blind and placebo-controlled trial with 331 patients, and is supported by two open-label studies.
Thanks For Watching
Appreciating a lot your feedback
